Su Xinyi

Dr Su graduated with MB BChir PhD from the University of Cambridge (UK) and joined IMCB in 2016 as a clinician-scientist. She balances her time leading a broad retinal research program as Senior Principal Investigator at IMCB with providing clinical leadership as Senior Consultant Vitreo-Retinal Surgeon at the National University Hospital. Dr Su also holds joint appointments as Research Director at the Department of Ophthalmology, National University of Singapore, and Clinician-Scientist at the Singapore Eye Research Institute. Her research interests focus on harnessing biomaterial, regenerative stem-cell, and nucleic acid technologies for the treatment of age-related retinal degenerative disease. Her research has been published in, inter alia, Nature Biomedical Engineering, Nature Communications, Lancet Global Health, PNAS, and Advanced Materials. She has a career total of over SGD25 million in competitive research grants, and is the recipient of multiple global and national awards, including the Asia-Pacific Academy of Ophthalmology’s Young Ophthalmologist Award (2019), the Asia-Pacific Vitreo-Retinal Society Leadership Development Program Gold Award (2020), Ten Outstanding Young Persons of Singapore Award (for Medical Innovation, 2021), the Susan Lim Outstanding Stem Cell Young Investigator Award (2022) and National Medical Research Council Clinician Scientist Award (2022). In 2022, she was accepted into the prestigious international membership of The Macular Society. Passionate about clinical translation of research, Dr Su holds several patents and co-founded an ISO 13485 (Medical Device Quality System) accredited spin-off company, Vitreogel Innovations, focussed on developing the next generation of vitreous substitutes. Beyond research, Dr Su is committed to people development and has mentored numerous clinician-scientists as the Deputy Director of the Clinician-Scientist Academy, National University Health System.